<DOC>
	<DOCNO>NCT00688688</DOCNO>
	<brief_summary>The study intend test safety , tolerability , efficacy two dos long term daily ( qd ) treatment Mirabegron patient symptoms overactive bladder secondly compare active comparator .</brief_summary>
	<brief_title>Study Test Long Term Safety Efficacy Beta-3 Agonist Mirabegron ( YM178 ) Patients With Symptoms Overactive Bladder</brief_title>
	<detailed_description>Patients complete 178-CL-046 ( NCT00689104 ) 178-CL-047 ( NCT00662909 ) new patient could enrol study eligible .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Patient willing able complete micturition diary questionnaire correctly Patient symptom overactive bladder ≥ 3 month Patient experience frequency micturition average ≥ 8 time per 24hour period 3day micturition diary period Patient must experience least 3 episode urgency ( grade 3 4 ) without incontinence , 3day micturition diary period Patient breastfeeding , pregnant , intend become pregnant study , childbearing potential , sexually active practice highly reliable method birth control Patient significant stress incontinence mixed stress/urge incontinence stress predominant factor Patient indwelling catheter practice intermittent selfcatheterization Patient diabetic neuropathy Patient evidence symptomatic urinary tract infection , chronic inflammation interstitial cystitis , bladder stone , previous pelvic radiation therapy previous current malignant disease pelvic organs Patient receives nondrug treatment include electrostimulation therapy Patient severe hypertension Patient know suspected hypersensitivity tolterodine , anticholinergic , YM178 , betaadrenoreceptor ( ßAR ) agonists , lactose inactive ingredient Patient treat investigational drug device within 30 day ( 90 day UK clinical study except 178CL046 ) Patient average total daily urine volume &gt; 3000 mL record 3day micturition diary period Patient serum creatinine &gt; 150 umol/L , aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 2x upper limit normal range ( ULN ) , gammaglutamyl transpeptidase ( γGT ) &gt; 3x ULN Patient clinically significant abnormal electrocardiogram ( ECG )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Overactive Bladder</keyword>
	<keyword>Frequency</keyword>
	<keyword>Micturition</keyword>
	<keyword>Urgency</keyword>
	<keyword>Urinary incontinence</keyword>
	<keyword>Urinary urge incontinence</keyword>
</DOC>